These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 795780)

  • 21. Antiparkinson medication in the treatment of extrapyramidal side effects: single of multiple daily doses?
    Neu C; Dimascio A; Demirgian E
    Curr Ther Res Clin Exp; 1972 May; 14(5):246-51. PubMed ID: 4623975
    [No Abstract]   [Full Text] [Related]  

  • 22. Dosage of neuroleptic drugs for schizophrenic patients (analysis of hospital cases in the psychiatric hospital during 1969 to 1973).
    Topiar A; Kanczucká V
    Act Nerv Super (Praha); 1975 Sep; 17(3):203. PubMed ID: 1199692
    [No Abstract]   [Full Text] [Related]  

  • 23. Antiparkinsonian agents and long-term neuroleptic treatment. Effect of G 31.406, orphenadrine, and placebo on parkinsonism, schizophrenic symptoms, depression and anxiety.
    Gerlach J; Rasmussen PT; Hansen L; Kristjansen P
    Acta Psychiatr Scand; 1977 Apr; 55(4):251-60. PubMed ID: 324238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oxypertine in schizophrenic psychoses. Controlled clinical trial in two psychiatric hospitals.
    Vinar O; Hamouz V; Bastecký J
    Act Nerv Super (Praha); 1968 Oct; 10(3):315-7. PubMed ID: 4883240
    [No Abstract]   [Full Text] [Related]  

  • 25. [Long term neuroleptic therapy using fluspirilene and penfluridol].
    Haase HJ; Fischer D; Floru L; Frank T; Joseph K; Knaack M; Mohr W; Richter-Peill H; Steuer A; Wahl G; Walterbusch G; Zurborn R
    Nervenarzt; 1971 Dec; 42(12):632-7. PubMed ID: 5134761
    [No Abstract]   [Full Text] [Related]  

  • 26. A comparison of the effects of oxypertine and trifluoperazine in withdrawn schizophrenics.
    Hunt PV
    Br J Psychiatry; 1967 Dec; 113(505):1419-24. PubMed ID: 4865294
    [No Abstract]   [Full Text] [Related]  

  • 27. [Experimental design of a pilot study on amantadine in the extrapyramidal syndrome induced by neuroleptic drugs].
    Ferrari P; Robotti E; Nardini M
    Boll Chim Farm; 1972 Oct; 111(10):610-5. PubMed ID: 4566407
    [No Abstract]   [Full Text] [Related]  

  • 28. [Aspects of long-term therapy using long-term neuroleptics -- experiences and viewpoints related to practice].
    Floru L
    Fortschr Neurol Psychiatr Grenzgeb; 1978 Feb; 46(2):82-104. PubMed ID: 204561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A pilot study of pimozide in chronic schizophrenic patients.
    Sugerman AA
    Curr Ther Res Clin Exp; 1971 Nov; 13(11):706-13. PubMed ID: 5000718
    [No Abstract]   [Full Text] [Related]  

  • 30. Basic principles in the use of antipsychotic agents.
    Mason AS
    Hosp Community Psychiatry; 1973 Dec; 24(12):825-9. PubMed ID: 4148176
    [No Abstract]   [Full Text] [Related]  

  • 31. A pilot investigation in neuroleptic therapy.
    Mattke DJ
    Dis Nerv Syst; 1968 Aug; 29(8):515-24. PubMed ID: 4877897
    [No Abstract]   [Full Text] [Related]  

  • 32. Our experience with octoclothepine therapy.
    Klíma V; Koutská M; Koutský J
    Act Nerv Super (Praha); 1972; 14(2):89-90. PubMed ID: 5040175
    [No Abstract]   [Full Text] [Related]  

  • 33. [Approach to resistance to treatment by neuroleptic combinations].
    Daskalopoulos NT; Cottereau MJ; Picchi E
    Ann Med Psychol (Paris); 1977 Jul; 2(2):333-51. PubMed ID: 596765
    [No Abstract]   [Full Text] [Related]  

  • 34. [Drug withdrawal symptoms following cessation of prolonged neuroleptic therapy].
    Krystof J; Zyg J; Mitkiewicz S; Kaczyński J
    Psychiatr Pol; 1971; 5(4):417-23. PubMed ID: 5112317
    [No Abstract]   [Full Text] [Related]  

  • 35. [Clinical evaluation of amantadine in the treatment of extrapyramidal syndromes caused by neuroleptic drugs].
    Bukowczyk A; Wasik A; Horodnicki J
    Psychiatr Pol; 1974; 8(2):143-8. PubMed ID: 4830321
    [No Abstract]   [Full Text] [Related]  

  • 36. Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia.
    Johnson DA
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):13-21. PubMed ID: 6143743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative study of TPS-23, chlorpromazine and placebo in chronic schizophrenic patients.
    Tetreault L; Bordeleau JM; Gauthier R; Vulpe M; Lapointe L
    Dis Nerv Syst; 1969 Feb; 30(2):Suppl:74-84. PubMed ID: 4886994
    [No Abstract]   [Full Text] [Related]  

  • 38. Malignant neuroleptic syndrome--its present status in Japan and clinical problems.
    Itoh H; Ohtsuka N; Ogita K; Yagi G; Miura S; Koga Y
    Folia Psychiatr Neurol Jpn; 1977; 31(4):559-76. PubMed ID: 608659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Possible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects.
    Kinon BJ; Kane JM; Chakos M; Munne R
    Psychopharmacol Bull; 1993; 29(3):365-9. PubMed ID: 7907184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical evaluation of a new neuroleptic "thiothixene" (p-4657 b).
    Gómez-Martínez I
    Psychiatr Neurol (Basel); 1967; 153(4):219-25. PubMed ID: 5340209
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.